KUMAR AMIT 4

What Happened

• Amit Kumar, CEO of Anixa Biosciences, acquired 21,000 common shares on June 12, 2026. The reported purchase price was $2.50 per share, for a total transaction value of $52,500. This was reported on a Form 4 filed June 16, 2026.
• This was a purchase (code P), which is generally treated as a direct insider buy rather than a sale.

Key Details

• Transaction date and price: June 12, 2026 — 21,000 shares at $2.50 per share (total $52,500).
• Filing date: Form 4 filed June 16, 2026 (four days after the transaction). This appears to exceed the SEC’s typical 2-business-day reporting window.
• Shares owned after the transaction: Not specified in the information provided in this summary.
• Footnotes/notes: No 10b5-1 plan, tax withholding, or other special notations were provided here.

Context

• Insider purchases can be viewed as a more informative signal than routine sales because they represent the insider committing personal capital; however, filings alone do not prove motivation.
• The filing delay reduces the timeliness of the disclosure; late Form 4s can make it harder for investors to act on insider activity promptly.